cannabinoids Archives - Page 15 of 15

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

June 10, 2019 Anti-inflammatory properties, Arthritis, Autoimmunity, Cannabinoids, Cannabis Science, CB1, CB2, Future Medicine, Muscle Pain, Neuropathy, Science, Synthetic Cannabinoids

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists Download

This paper is also stored here: http://bit.ly/2HZ6cWb inside the CED Foundation Archive

To explore related information, click keywords:

Certain Cannabinoids may be Effective Co-Therapies for Neuropathic or MS pain

June 5, 2019 Cannabinoids, Cannabis Education, Cannabis Science, Neuropathy, Pain

In a systematic review of studies investigating cannabis therapy for the treatment of chronic non-cancer pain (CNCP), evidence pointed to cannabinoids primarily effecting change with respect to neuropathy or MS-related pain. For CNCPs, it is unlikely that cannabinoids can be used as a single therapy, but rather in conjunction with other therapies. The quality of evidence in many of the studies reviewed was low, so further research needs to be completed in order to evaluate the efficacy of cannabinoids as a long-term treatment option for CNCPs.

Biosynthesis of Cannabinoids

June 4, 2019 Biosynthesis, Cannabinoids

Still in the early stages, biosynthesis of cannabinoids using fermentative microbes could diminish dependency on plants to extract cannabinoids and help control dosage for medical patients. This is still in the works but could be very cost efficient long term for all involved http://bit.ly/315Lcof